FERTILITY CAPSULE VIII (AMH, LH, FSH, PROLACTIN, E2, TSH, TESTOSTERONE TOTAL)

Fertility Capsule VIII is a comprehensive blood-test panel that measures Anti-Müllerian Hormone (AMH), Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), prolactin, estradiol (E2), Thyroid-Stimulating Hormone (TSH) and total testosterone. These hormones participate in ovarian function, egg development, ovulation, menstrual-cycle regulation, sperm production, sexual function and thyroid control. Testing them together provides a broad hormonal overview for people undergoing fertility evaluation.

In females, AMH provides information about ovarian reserve, while FSH, LH and estradiol help assess ovarian and pituitary function. Prolactin and thyroid abnormalities may interfere with menstrual regularity and ovulation. Total testosterone can support the assessment of androgen excess, including symptoms associated with polycystic ovary syndrome (PCOS). In males, FSH, LH and testosterone contribute information about testicular hormone function and sperm-production signalling, while prolactin and TSH may help identify endocrine factors affecting fertility or sexual function.

This panel does not independently diagnose infertility, confirm ovulation, determine egg quality, assess fallopian-tube patency or evaluate semen quality. Fertility is influenced by age, reproductive anatomy, sperm health, timing, medical conditions and several other factors. Results should therefore be interpreted by a qualified doctor together with clinical history, examination and additional investigations.

Benefits of the Test

• Measures seven important hormones associated with reproductive and endocrine function.
• Provides information about ovarian reserve through AMH measurement.
• Helps assess ovarian, pituitary and testicular hormone signalling.
• Supports evaluation of irregular periods, absent periods and suspected ovulatory problems.
• May help identify hormonal patterns associated with PCOS.
• Assesses prolactin and thyroid-related factors that may affect fertility.
• Supports investigation of androgen excess or low-testosterone symptoms.
• May assist fertility specialists in planning further evaluation or treatment.
• Provides multiple related hormone results from one blood collection.

Why Doctors Recommend This Test

A doctor may recommend this panel when a couple is experiencing difficulty conceiving or when an individual has symptoms suggesting a reproductive hormone imbalance. In females, these symptoms may include irregular or absent menstrual periods, difficulty predicting ovulation, acne, excessive facial or body hair, scalp hair thinning, unexplained nipple discharge or symptoms of early ovarian insufficiency. The panel may also be used before selected fertility treatments.

AMH is produced by cells within developing ovarian follicles. It is commonly used to estimate ovarian reserve, meaning the approximate remaining supply of eggs. AMH may help predict how the ovaries could respond to fertility medicines, but it cannot determine egg quality or guarantee natural conception or treatment success. Age and other fertility factors remain important even when AMH is within the expected range.

FSH and LH are produced by the pituitary gland. In females, they help regulate follicle development, ovulation and menstrual-cycle function. Estradiol is a major form of estrogen produced primarily by the ovaries and changes throughout the menstrual cycle. Doctors often interpret FSH, LH and E2 together because the menstrual-cycle day and relationship between the hormones provide clinically useful information.

Prolactin is also produced by the pituitary gland. A persistently elevated prolactin level may interfere with reproductive hormone signalling, menstrual periods and ovulation. In males, high prolactin may be associated with reduced sexual desire, erectile difficulties or reduced testosterone. Temporary elevations can occur because of stress, sleep, exercise, breast stimulation and certain medicines, so an unexpected result may need confirmation.

TSH is produced by the pituitary gland and controls thyroid-hormone production. Both underactive and overactive thyroid function may affect menstrual cycles, ovulation, sexual function and reproductive health. An abnormal TSH result may require free T4, thyroid antibodies or other investigations.

Total testosterone measures both protein-bound and unbound testosterone circulating in the blood. In females, increased testosterone may support the evaluation of androgen excess or PCOS when assessed with symptoms and other findings. In males, low testosterone may be associated with reduced libido, erectile problems, reduced muscle mass or impaired reproductive function. A semen analysis is still required to assess sperm count, movement and morphology directly.

Preparation Before Test

A venous blood sample is collected from a vein in the arm. Fasting is not always required for this panel, but the doctor or laboratory may recommend morning collection or fasting depending on the clinical purpose and any additional tests ordered. Follow the instructions provided by Focus Diagnostics.

For females, inform the laboratory and doctor about the first day of the last menstrual period, usual cycle length, pregnancy status and use of fertility medicines or hormonal contraception. FSH, LH and estradiol vary during the menstrual cycle. When the purpose is baseline fertility assessment, a doctor may request collection during the early follicular phase, commonly around cycle days 2 to 5. AMH can generally be measured on any cycle day, but the timing of the complete panel should follow the doctor's instructions.

Total testosterone is often assessed in the morning because concentrations may change during the day, particularly in males. A doctor may recommend confirmation with another morning sample if the result is unexpectedly low. Prolactin may rise temporarily because of sleep, emotional stress, strenuous exercise, sexual activity or nipple stimulation. Patients may be asked to collect the sample a few hours after waking and rest quietly before collection.

Inform the doctor about every prescribed medicine, non-prescription medicine, vitamin and supplement being taken. Fertility medicines, hormonal contraceptives, estrogen, testosterone, anabolic steroids, thyroid medicines, antipsychotics, antidepressants, anti-nausea medicines and several other treatments may influence one or more results. Biotin supplements can interfere with certain laboratory immunoassays. Do not stop any medicine or supplement unless instructed by the treating doctor.

Tell the healthcare professional about pregnancy, breastfeeding, recent illness, thyroid disease, pituitary disease, PCOS, ovarian surgery, cancer treatment, intense exercise or recent changes in body weight. These factors may influence hormone concentrations or their interpretation.

Normal Reporting Time

Fertility Capsule VIII is generally reported within 24 to 48 hours after the laboratory receives an acceptable blood sample. The exact turnaround time may vary because the panel contains multiple hormone assays and AMH testing may be processed according to the laboratory's testing schedule.

Reporting may take longer when a result requires repeat analysis, dilution, quality verification or clinical correlation. Patients requiring results before a fertility appointment or treatment cycle should confirm the expected reporting time with the collection centre.

Who Should Take This Test?

This panel may be recommended for women experiencing difficulty becoming pregnant, irregular or absent periods, suspected ovulatory dysfunction, symptoms of PCOS or concerns about ovarian reserve. It may also be considered before assisted reproductive treatments such as ovulation induction, intrauterine insemination or in vitro fertilisation when advised by a fertility specialist.

Women with symptoms such as acne, excess facial hair, scalp hair thinning, unexpected nipple discharge, hot flushes at a younger age or significant menstrual changes may require hormonal evaluation. However, the appropriate tests depend on the symptoms, and this panel may not contain every investigation required.

In males, the panel may support evaluation of infertility, reduced sexual desire, erectile problems, low testosterone symptoms or suspected pituitary or testicular dysfunction. Male fertility assessment generally also requires semen analysis because hormone tests cannot directly measure sperm concentration, motility or morphology.

Testing may also be considered when a doctor suspects thyroid or prolactin-related reproductive problems. It should not be used as a general fertility guarantee in people without a clinical indication. A healthcare professional should determine whether the complete panel or selected individual hormone tests are appropriate.

Understanding the Hormones

AMH: AMH is produced by small developing follicles in the ovaries. Higher concentrations generally indicate a larger ovarian follicle pool, while lower concentrations may indicate reduced ovarian reserve. AMH normally decreases with age. High levels may occur in some women with PCOS. AMH does not measure egg quality, confirm ovulation or predict with certainty whether pregnancy will occur.

FSH: FSH stimulates ovarian follicles in females and supports sperm production in males. In females, a high early-cycle FSH result may be associated with reduced ovarian response or ovarian insufficiency, while a low result may occur with pituitary or hypothalamic dysfunction. Interpretation requires the menstrual-cycle day and estradiol level. In males, increased FSH may be associated with impaired testicular sperm production, while low levels may indicate reduced pituitary stimulation.

LH: LH helps trigger ovulation and supports progesterone production after ovulation in females. In males, it stimulates testosterone production in the testes. Abnormal LH patterns may occur with PCOS, ovarian dysfunction, testicular dysfunction or pituitary and hypothalamic disorders. A single LH measurement does not reliably confirm that ovulation has occurred.

Prolactin: Prolactin supports breast development and milk production. Excess prolactin outside pregnancy or breastfeeding may disrupt reproductive hormone signalling. Causes can include medicines, hypothyroidism, pituitary conditions, pregnancy and temporary physiological factors. A mildly elevated result may need repeat testing under standardised conditions.

Estradiol (E2): Estradiol is a principal estrogen during the reproductive years. It supports follicle development, the menstrual cycle and the uterine lining. Its concentration changes significantly across the cycle. Early-cycle estradiol is commonly interpreted with FSH, while results collected at other times require different clinical interpretation.

TSH: TSH regulates the thyroid gland. An increased or decreased result may indicate altered thyroid function, but TSH alone may not establish the cause. Free T4 and other thyroid tests may be required. Pregnancy and fertility-treatment planning may involve clinical targets different from the laboratory's general adult reference interval.

Total Testosterone: Testosterone contributes to reproductive and sexual function in all sexes. High levels in females may be associated with PCOS, medicine use or less common ovarian or adrenal conditions. Low levels in males may reflect testicular, pituitary, hypothalamic or systemic conditions. An abnormal result may require repeat morning testing, SHBG, free testosterone or other hormone tests.

Detailed Information

Fertility depends on coordinated communication between the hypothalamus, pituitary gland, ovaries or testes, thyroid gland and reproductive organs. The hypothalamus releases signals that stimulate the pituitary gland to produce FSH and LH. These hormones then act on the ovaries or testes, which produce sex hormones and support egg development or sperm production. Prolactin and thyroid function can influence this system.

Because these hormones interact, doctors interpret the pattern rather than treating every result separately. For example, high FSH accompanied by an appropriate estradiol result may have a different meaning from high FSH with elevated estradiol. Likewise, low testosterone with elevated LH may suggest a different source than low testosterone with low or inappropriately normal LH.

Hormone concentrations change with age, sex, menstrual-cycle phase, pregnancy, time of day, medicines and laboratory method. Reference intervals are therefore not universal. Patients should use the reference ranges printed on their own report and avoid comparing results with values from another laboratory or an online fertility calculator.

A normal panel does not exclude infertility. Female fertility evaluation may additionally include pelvic ultrasound, antral follicle count, assessment of ovulation, tubal-patency testing and examination of the uterus. Male evaluation commonly includes semen analysis and, when indicated, physical examination, ultrasound or genetic testing. Both partners may need assessment because fertility difficulties can involve female factors, male factors, combined factors or remain unexplained.

An abnormal result does not automatically indicate permanent infertility. Some abnormalities are temporary, medicine-related or manageable. Repeat testing or additional investigations may be needed before a diagnosis is made. Treatment decisions, fertility medicines or hormonal supplements should not be started or changed solely from this panel without medical guidance.